|
PASG | Passage Bio, Inc. |
|
|
PASG | Passage Bio, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 1.97 |
| Leverage | 40.18% |
| Market Cap | $ 31.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -64.5m |
| Margin | -1151.70% |
Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.